Share
Market Research Report

AAV GENE THERAPY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Segmentation
  • By Vector SerotypeAAV9 · AAV2 · AAV5 · AAV8 · AAV1 · and Engineered/Synthetic AAV Variants
  • By Therapeutic AreaNeurological Disorders · Ophthalmic Disorders · Rare Genetic Disorders · Hematological Disorders · Muscular Disorders · Metabolic Disorders · Cardiovascular Disorders · Oncology · and Others
  • By Target TissueCentral Nervous System · Eye/Retina · Liver · Muscle · Lung · Heart · and Blood/Bone Marrow By Route of Administration: Intravenous · Intrathecal · Intracerebral · Subretinal · Intravitreal · Intramuscular · and Intracardiac
  • By Indication TypeMonogenic Disorders and Polygenic Disorders
  • By Gene Payload TypeGene Replacement · Gene Silencing · and Gene Augmentation
  • By Development StagePreclinical · Phase I · Phase II · and Phase III
  • By Manufacturing TypeIn-house Manufacturing and Contract Manufacturing (CDMO/CMO)
  • By End UserBiopharmaceutical Companies · Research Institutes and Academic Centers · Hospitals and Specialty Clinics · and Others (CROs)
  • By GeographyNorth America · Europe · Asia Pacific · Latin America · Middle East · and Africa
  • Published In01 Apr 2026
  • Report CodeCMI9108
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026-2033

Market Segmentation

  • Vector Serotype Insights (Revenue, USD Bn, 2021 - 2033)

    • AAV9
    • AAV2
    • AAV5
    • AAV8
    • AAV1
    • Engineered/Synthetic AAV Variants

  • Therapeutic Area Insights (Revenue, USD Bn, 2021 - 2033)

    • Neurological Disorders
    • Ophthalmic Disorders
    • Rare Genetic Disorders
    • Hematological Disorders
    • Muscular Disorders
    • Metabolic Disorders
    • Cardiovascular Disorders
    • Oncology
    • Others

  • Target Tissue Insights (Revenue, USD Bn, 2021 - 2033)

    • Central Nervous System
    • Eye/Retina
    • Liver
    • Muscle
    • Lung
    • Heart
    • Blood/Bone Marrow

  • Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)

    • Intravenous
    • Intrathecal
    • Intracerebral
    • Subretinal
    • Intravitreal
    • Intramuscular
    • Intracardiac

  • Indication Type Insights (Revenue, USD Bn, 2021 - 2033)

    • Monogenic Disorders
    • Polygenic Disorders

  • Gene Payload Type Insights (Revenue, USD Bn, 2021 - 2033)

    • Gene Replacement
    • Gene Silencing
    • Gene Augmentation

  • Development Stage Insights (Revenue, USD Bn, 2021 - 2033)

    • Preclinical
    • Phase I
    • Phase II
    • Phase III

  • Manufacturing Type Insights (Revenue, USD Bn, 2021 - 2033)

    • In-house Manufacturing
    • Contract Manufacturing (CDMO/CMO)

  • End User Insights (Revenue, USD Bn, 2021 - 2033)

    • Biopharmaceutical Companies
    • Research Institutes and Academic Centers
    • Hospitals and Specialty Clinics
    • Others (CROs)

  • Regional Insights (Revenue, USD Bn, 2021 - 2033)

    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa